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Abstract
Background: Recurrent (RP) and chronic pancreatitis (CP) may complicate Cystic Fibrosis (CF). It is still unknown if
mutations in genes involved in the intrapancreatic activation of trypsin (IPAT) or in the pancreatic secretion
pathway (PSP) may enhance the risk for RP/CP in patients with CF.
Methods: We enrolled: 48 patients affected by CF complicated by RP/CP and, as controls 35 patients with CF
without pancreatitis and 80 unrelated healthy subjects. We tested a panel of 8 genes involved in the IPAT,
i.e. PRSS1, PRSS2, SPINK1, CTRC, CASR, CFTR, CTSB and KRT8 and 23 additional genes implicated in the PSP.
Results: We found 14/48 patients (29.2%) with mutations in genes involved in IPAT in the group of CF patients
with RP/CP, while mutations in such genes were found in 2/35 (5.7%) patients with CF without pancreatitis and in
3/80 (3.8%) healthy subjects (p < 0.001). Thus, we found mutations in 12 genes of the PSP in 11/48 (22.9%) patients
with CF and RP/CP. Overall, 19/48 (39.6%) patients with CF and RP/CP showed one or more mutations in the genes
involved in the IPAT and in the PSP while such figure was 4/35 (11.4%) for patients with CF without pancreatitis
and 11/80 (13.7%) for healthy controls (p < 0.001).
Conclusions: The trans-heterozygous association between CFTR mutations in genes involved in the pathways of
pancreatic enzyme activation and the pancreatic secretion may be risk factors for the development of recurrent or
chronic pancreatitis in patients with CF.
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Background
Cystic Fibrosis (CF) is the most common inherited
autosomal recessive disease in Caucasians. It is caused
by defects in the CF transmembrane conductance regula-
tor (CFTR) gene, which encodes a cAMP-regulated chlor-
ide channel. Defects in the CFTR protein cause abnormal
chloride transport across the apical membranes of epithe-
lial cells in the airways, pancreas, intestine, vas deferens,
and sweat glands leading to progressive lung disease,
pancreatic dysfunction, male infertility, and elevated sweat
electrolytes, respectively (Castellani & Assael, 2017).
About 85% of individuals affected by CF suffer from
pancreatic insufficiency (PI), in most cases since the birth.
However, 15% of the patients retain pancreatic sufficiency
(PS) that permits adequate digestion (Walkowiak et al.,
2008). About 85% of individuals affected by CF suffer
from pancreatic insufficiency (PI), in most cases since
the birth. However, 15% of the patients retain pancre-
atic sufficiency (PS) that permits adequate digestion
(Walkowiak et al., 2008).
Recurrent pancreatitis (RP) and chronic pancreatitis
(CP) may complicate CF. It was firstly mentioned by
Shwachman et al. in 1975 (Shwachman et al., 1975).
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They reported, in a period of 20 years in 2000 patients
with CF, 10 cases of pancreatitis (0.5%), all with PS.
Currently, a frequency of recurrent/chronic pancreatitis
between 17% (Durno et al., 2002) and 22% (Ooi et al.,
2011) is estimated in patients with CF.
The dysfunction of the CFTR protein has a role in the
pathogenesis of pancreatitis because it causes the
impaired secretory function of pancreatic duct cells and
the altered flow of digestive pro-enzymes into the
duodenum triggering recurrent episodes of pancreatitis
that in some patients may evolve to chronic pancreatitis
(Walkowiak et al., 2008; Lew et al., 2017). This compli-
cation is more frequent in patients with CF and PS (that
frequently have at least one class IV-V CFTR mutation),
in which pancreatic acinar islets still produce pancreatic
enzymes that may be prematurely activated within the
pancreas. Recurrent/chronic pancreatitis has been
observed also independently by the development of CF.
In fact, Bishop et al. showed a frequency up to 30% of
RP/CP in subjects carrying only one CFTR mutation in
the absence of any sign of CF (Bishop et al., 2005). How-
ever, only a small percentage of patients with CFTR muta-
tions or with CF experience RP or CP, suggesting that other
risk factors must be involved (Walkowiak et al., 2008).
In fact, in addition to CFTR, patients with idiopathic
recurrent or chronic pancreatitis have been investigated
for other genes related to the premature intra-pancreatic
activation of trypsin pathway. The first gene related to
pancreatitis was the cationic trypsinogen gene protease
serine 1 (PRSS1) in 1996: a gain of function missense
mutation i.e., the R122H, was identified as a risk factor
for CP (Whitcomb et al., 1996). In the following years,
loss-of-function variants in the pancreatic secretory tryp-
sin inhibitor (SPINK1) (Chen et al., 2000), calcium-sensing
receptor (CASR) (Felderbauer et al., 2003) and chymotryp-
sinogen C (CTRC) (Szmola & Sahin-Toth, 2007) genes,
firmly established the pivotal role of prematurely activated
trypsin within the pancreas in the etiology of pancreatitis.
Moreover, our group demonstrated that mutations in sev-
eral dozens of genes bearing to six different pancreatic
pathways represent risk factors for recurrent/chronic
pancreatitis (Sofia et al., 2016) reinforcing the concept that
trans-heterozygous mutations in different genes are
involved in the pathogenesis of idiopathic pancreatitis.
Interestingly, we described trans-heterozygosity for
mutations in different genes also in a patient with CF
and RP that was compound heterozygous for the
[delta]F508 and G91G CFTR mutations and had a
pathogenic mutation in the CTRC gene (Tomaiuolo et
al., 2015).
Thus, to better define the role of trans-heterozygosity
for mutations in different genes as a risk factor for RP/CP
in patients with CF, in this study we investigated a cohort
of CF patients with RP/CP in comparison to patients with
CF without pancreatitis and to healthy subjects to
compare the frequency of mutations in a panel of genes
related to the intra-pancreatic activation of trypsin (IPAT)
and a group of other genes related to pancreatic secretion
pathways (PSP) previously reported to contribute to to the
pathogenesis of pancreatitis (Sofia et al., 2016).
Methods
Patients
The informed consent was obtained from all patients or
from the parents or guardians of minors. The study was
approved by the Ethical Committee (Scientific Board of
“Bambino Gesù” Children’s Hospital, IRCCS, Rome, Italy)
and was conducted in accordance with the Helsinki
Declaration.
We enrolled 48 unselected patients affected by CF
complicated by RP or CP recruited through a multi-
centric study involving 9 Italian CF centres. The main
data (i.e., age at diagnosis of CF, age at diagnosis of RP/
CP, CFTR genotype and pancreatic status) are reported
in Table 2. As control populations, we studied 35
unselected patients with CF without symptoms or his-
tory of pancreatitis (see Table 3 for the data of age at
diagnosis of CF, CFTR genotype and pancreatic status)
and 80 unrelated, adult healthy subjects of the same eth-
nic group of the patients with CF (i.e., Italian from at
least two generations) whose DNA samples and anon-
ymized clinical data (in particular absence of CF and of
any pancreatic disorder) were available, in the biological
bank of our Institution.
The diagnosis of CF was done according to the inter-
national criteria (Farrell et al., 2017). Pancreatic sufficiency
in patients with CF was defined on the basis of two values
of faecal pancreatic elastase > 200 mg/g measured in sub-
jects free from acute gastrointestinal events (Walkowiak et
al., 2016) or on the basis of normal 72-h fecal fat balance
(Walkowiak et al., 2008). Recurrent pancreatitis was diag-
nosed in patients that had at least two episodes of acute
pancreatitis (at a distance of at least six months after the
resolution of the previous episode) each one with abdom-
inal pain (once excluded other causes) in association with
the increase of serum lipase (at least 2X the upper refer-
ence limit) and/or imaging evidence (e.g., pancreatic
edema, hemorrhage or necrosis) (Morinville et al., 2012;
Kumar et al., 2016). Chronic pancreatitis was diagnosed
according to the M-ANNHEIM criteria (Schneider et al.,
2007) in patients in which instrumental analysis revealed
calcifications or characteristic ductal changes. All the
patients with CP had a positive anamnesis for episodes of
recurrent pancreatitis.
Next-generation targeted sequencing of pancreatic genes
Targeted resequencing was performed using a uniquely
customized design TruSeq Custom Amplicon Low Input
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technology (Illumina, San Diego, CA) with the MiSeq
sequencing platform (Illumina). This technology is a
fully integrated DNA-to-data solution, including online
probe design and ordering through the Illumina website,
sequencing assay, automated data analysis, and offline
software for reviewing results. Online probe design was
performed by entering target genomic regions into Design
Studio software (Illumina). We designed a panel of eight
genes included in IPAT genes (Sofia et al., 2016; Chen &
Férec, 2009; Mahurkar et al., 2006; Cavestro et al., 2003):
CFTR (NM_000492.3), SPINK1 (NM_003122.3), PRSS1
(NM_002769.4), protease, serine 2 (PRSS2) (NM_002770.2),
CTRC (NM_007272.2), CASR (NM_001178065.1), cathep-
sin B (CTSB) (NM_147780.2) and keratin 8 (KRT8)
(NM_002273). The sequence of these genes was obtained
consulting the University of California, Santa Cruz,
Genome Browser Home (https://genome.ucsc.edu/cgi-bin/
hgGateway, last accessed October 2015) with a coverage of
100%. MiSeq system provides fully integrated
on-instrument data analysis software. Each single variant
reported in the vCard output file was evaluated for the
coverage and the Q score and visualized via Integrative
Genomics Viewer (Thorvaldosdottir et al., 2013; Robinson
et al., 2011). All mutations identified by MiSeq Reporter
were validated by Sanger sequencing using standard
protocols.
In the second step, we selected the genes encoding
proteins related to the pancreatic activation of zymogens
(Sofia et al., 2016). Such genes were selected among the
genes annotated in the “Pancreatic Secretion Pathway”
(map04972), available in the KEGG database (Kanehisa
et al., 2014). The 23 genes selected were classified into
four groups according to the activity of the encoded pro-
tein or their role in the pathogenesis of pancreatitis: (i)
genes encoding proteins involved in pancreatic secretion
and ion homeostasis (PPY, F2RL1, TMPRSS15, SCL4A2,
SLC4A4, SLC26A3, CPB1, CLPS) (Berni Canani et al.,
2010; Sharma et al., 2005; Stevens et al., 2004; Multigner
et al., 1985); (ii) genes encoding proteins involved in cal-
cium (Ca2+) signalling and zymogen granules exocytosis
(PRKCD, ITPR3, GP2, TRPC3, STIM1, ATP2C2,
TRPV1, TRPV5, TRPV6, PIK3CG (Jin et al., 2015;
Williams, 2008; Ramnath et al., 2010; Lupia et al.,
2004); (iii) genes encoding proteins involved in au-
tophagy (HSP90AA1, LAMP2, MAP1LC3B) (Willemer et
al., 1989; Gukovskaya & Gukovsky, 2012; Fortunato &
Kroemer, 2009) and (iv) autoimmune pancreatitis-related
genes (CA4, ABCF1) (Ohmuraya & Yamamura, 2008). To
search mutations in such genes, we used the targeted
resequencing performed by a uniquely customized design:
TruSeq Custom Amplicon Low Input Kit (Illumina) with
the MiSeq sequencing platform (Illumina). The probe
design (locus-specific oligos) was carried out by entering
the target genomic regions into Design Studio software
(Illumina). The design was performed over a cumulative
target region of 99.328 bp and generated a panel of 677
amplicons with a coverage of 100% of the cumulative re-
gion. Library preparation and sequencing runs have been
performed according to the manufacturer’s procedure.
Only the PRSS2 gene was analyzed by Sanger sequen-
cing because its genomic sequence was updated in
the University of California Santa Cruz (UCSC) genome
database after the design of the resequencing panel.
Data and bioinformatic analysis
The MiSeq Reporter software, a data analysis software
included in the MiSeq system, performs secondary
analysis on the base calls and quality score (Qscore)
generated by the Real-Time Analysis software during the
sequencing run and provides a list of all detected vari-
ants compared with the reference genome (Homo
sapiens, hg19, build 37.2). Each single variant reported
in the output file was evaluated for the coverage and the
Qscore and visualized via the Integrative Genome
Viewer (Thorvaldosdottir et al., 2013). Based on the
guidelines of the American College of Medical Genetics
and Genomics (Rehm et al., 2013), all regions that had
been sequenced with a sequencing depth < 30 were
considered not suitable for the analysis. Furthermore, we
established a minimum threshold in Qscore of 30 (base
call accuracy of 99.9%). All identified variants were
analyzed with bioinformatic softwares evaluating the
impact of change in amino-acidic structure on protein
functionality with several parameters, and we filtered all
variants to retain those alterations with a high
disease-causing potential. We used four tools based on
different parameters: PolyPhen-2 (Adzhubei et al., 2010),
Align-GVGD (Mathe et al., 2006; Hicks et al., 2011),
DNA SIFT (Ng & Henikoff, 2001) and MutationTaster
(Schwarz et al., 2010). To facilitate the analysis of the
potential splicing mutations, we used Human Splicing
Finder to predict the effects of mutations on splicing
signals or motifs in any human sequence (Desmet et al.,
2009). Sanger sequencing using standard protocols
validated the variants that have been predicted as
“damaging” by at least three tools. For each of these
mutations we assessed the frequency in the general
population reported by the ExAC (Exome Aggregation
Consortium) tool.
Results
All individuals from the three groups, i.e., patients with
CF and RP/CP (n = 48), patients with CF and without
pancreatitis (n = 35) and healthy subjects (n = 80) were
investigated for mutations in the 8 genes encoding
proteins involved in IPAT and in the 23 genes encoding
proteins involved in the PSP (Table 1). All the 48 pa-
tients with CF and RP/CP (Table 2) and the 35 with CF
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without pancreatitis (Table 3) had a pathological sweat
test (i.e., > 60 mEq/L) with the exception of a patient
with CF without pancreatitis that had a value of
53 mEq/L, and all patients from both the groups had
two CFTR mutations with the exception of a patient
with CF and RP in which only one mutation was known.
Among the 48 patients with CF and RP/CP we found 39
patients (81.2%) with PS and 9 patients with PI (18.8%);
these figures were 13/33 (30.4%) and 20 (69.6%), respect-
ively, among the patients with CF without pancreatitis
(p < 0.001).
As shown in Table 1 and Fig. 1a, in the group of
patients with CF and RP/CP we found 14/48 patients
(29.2%) with mutations in IPAT genes, while mutations
in such genes were found in 2/35 (5.7%) patients with
CF without pancreatitis (Table 1 and Fig. 1b) and in
3/80 (3.8%) healthy subjects (Table 1 and Fig. 1c) (chi
square: 20.4, p < 0.001).
Going to the type of mutations in IPAT genes in the
patients with CF and RP/CP: 2 were heterozygous for a
splicing mutation in PRSS1 in cis, 4 patients were
heterozygous for CTRC mutations, 3 patients were
heterozygous for PRSS2 mutations, 2 patients were
heterozygous for CASR mutations and 2 patients were
heterozygous for KRT8 mutations; 1 patient had a
splicing mutation in PRSS1 and a missense mutation in
KRT8 (Table 2). All these mutations were absent in our
controls and were found with a frequency < 1% in the
general population as annotated in the ExAC tool
(Additional file 1: Table S1). While, the 2 patients with
CF without pancreatitis had, in IPAT genes, a heterozy-
gous PRSS1/PRSS2 hybrid mutation and a heterozygous
missense mutation of CTRC, respectively (Table 3).
Finally, the three healthy subjects had all a heterozygous
missense mutation in the KRT8, CASR and SPINK1
genes, respectively (Table 4).
Thus, all individuals from the three groups were
studied for mutations in the 23 genes encoding pro-
teins of PSP. In the group of patients with CF and
RP/CP (Fig. 1a, Table 1, Table 2), the analysis revealed
mutations in 11/48 (22.9%) patients. While, as shown
in Fig. 1b and c and in Tables 3 and 4, mutations in
such genes were found in 3/35 (8.5%) patients with
CF without pancreatitis and in 8/80 (10%) healthy
subjects (chi square: 4.39; p = 0.11).
Going to the type of mutations, of the 11 patients with
CF and RP/CP (Table 2) 7 patients showed heterozygous
mutations, 1 displayed a homozygous mutation and 3
patients were trans-heterozygous for mutations in more
than one gene. Finally (Table 2 and Additional file 1:
Table S1), in this group of patients, we found 13 mis-
sense mutations in 12 genes encoding proteins of PSP:
(i) SLC4A2, TMPRSS15, SLC26A3 and SLC4A4 genes
encoding proteins involved in pancreatic secretion and
ion homeostasis; (ii) TRPV1, TRPV5, TRPV6, PIK3CG,
PRKCD and ATP2C2 genes encoding proteins involved
in calcium (Ca2+) signalling and zymogen granules
exocytosis and (iii) MAP1LC3B, LAMP2 genes encoding
proteins involved in autophagy. One nonsense homozy-
gous mutation was found in TRPV1. All these mutations
were not present in the 35 CF patients without pancrea-
titis and in the 80 healthy subjects (Table 2 and
Additional file 1: Table S1).
Among the 35 patients with CF without pancreatitis
(Table 3), one patient was trans-heterozygous for muta-
tions in the genes of both panels and 2 patients had
mutations only in the genes of the PSP. In the cohort of
healthy controls (Table 4), we found 7 individuals with
variants in at least one gene of the PSP.
All the mutations found in patients and controls had a
frequency < 1% in the general population (data not
shown).
Finally, 19/48 (39.6%) patients with CF and RP/CP had
mutations in at least one gene of the IPAT or PSP
pathway. While, this is true for 4/35 (11.4%) patients
with CF without CP and for 11/80 (13.7%) healthy sub-
jects, chi square: 14.5, p < 0.001 (Fig. 1 and Table 1).
Additional file 1: Table S1 reports a summary of all gene
mutations found in the three groups of subjects studied.
Discussion
Our study confirms that the occurrence of RP/CP is
more frequent in patients with CF and PS (Walkowiak et
al., 2008) and demonstrates that patients with CF and
RP/CP have a significantly higher frequency of muta-
tions in genes encoding proteins that may promote the
auto-activation of pancreatic proenzymes or regulate
pancreatic secretion. The small number of cases pre-
cluded clinical comparison between patients bearing
mutations and those wild-type for all genes tested. Thus,
Table 1 Number and % of subjects with mutations in IPAT genes; PSP genes and at least one gene (IPAT & PSP) in: patients with CF
and recurrent/chronic pancreatitis (RP/CP); patients with CF without pancreatitis and healthy subjects
n of cases IPAT PSP IPAT & PSP
CF and RP/CP 48 14 (29.2) 11 (22.9) 19 (39.6)
CF without pancreatitis 35 2 (5.7) 3 (8.5) 4 (11.4)
healthy subjects 80 3 (3.8) 8 (10) 11 (13.7)
Chi square and (p) 20.4 (p < 0.001) 4.39 (p = 0.11) 14.5 (p < 0.001)
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Table 2 Sweat chloride (mmol/L, SC), pancreatic status, age at CF and pancreatitis diagnosis, CFTR genotype and mutations in genes
related to intra-pancreatic activation of trypsin (IPAT) and pancreatic secretion pathway (PSP) genes in 48 patients with CF and
recurrent/chronic pancreatitis
ID SC Pancreatic status Diagnosis
of CF (Age)
RP/CP onset CFTR genotype IPAT genes PSP genes
1 117 S 19 Y 5 Y [delta]F508/c.2657 +
5G > A
/ /
2 77 S 20 Y 35 Y N1303 K/P205S / /
3 90 S 5 M 10 Y G85E/c.489 + 1G > T / TRPV1: c.755C > T (P252L)
4 109 S 3 M 17 Y G542X/c.2657 + 5G > A / SLC4A2: c.299G > T (R109L);
TRPV6: c.806C > T (T269 M)
5 77 I 2 M 8 M [delta]F508/I1027T / PIK3CG: c.1613C > T (P538L);
TMPRSS15: c.935C > T (T312I)
6 84 S 14 Y 26 Y R347P/R347P / /
7 100 S 2 M 4 Y c.2657 + 5G > A/c.2657
+ 5G > A
/ /
8 62 S 16 Y 16 Y [delta]F508/D110H / /
9 109 S 1 M 3 Y N1303 K/c.2657 + 5G >
A
/ /
10 80 S 7 M 19 Y c.2657 + 5G > A/L1077P / /
11 63 S 9 Y 24 Y W1282X/R347P / /
12 92 S 4 M 11 Y [delta]F508/D579G / /
13 66 S 1 M 3 Y c.579 + 1G > T/D1152H / /
14 74 S 43 Y 10 Y [delta]F508/D1152H PRSS1: c.[592-11C > T;c.592-
8C > T]
/
15 67 S 46 Y 12 Y [delta]F508/D1152H PRSS1: c.[592-11C > T;c.592-
8C > T]
/
16 60 S 10 Y 2 Y S1297 fs*5/D993G / /
17 90 S 1 Y 4 Y [delta]F508/
I1000_A1004del
/ /
18 85 I 5 M 3 Y [delta]F508/G85E CTRC: c.514A > G (K172E) TRPV1: c.1261C > T (R421X)•
19 106 S 12 Y 8 Y N1303 K/D579G / /
20 76 I 9 Y 18 Y [delta]F508/I1234V / /
21 78 S 11 Y 9 Y [delta]F508/G91G CTRC: c. 703G > A (V235I) PRKCD: c.1501G > T (G501 W);
MAP1LC3B: c.73G > C (E25Q)
22 73 S 1 Y 3 Y [delta]F508/S1255P / /
23 73 I 27 Y 34 Y Q220*/(V562I;A1006E) PRSS2: c.292A > T (K98X) SLC26A3: c.2276C > A (P759Q)
24 88 S 1 Y 17 Y [delta]F508/D1152H PRSS2: c.689C > T (T230I) SLC4A4: c.976A > G (I326V)
25 101 I 4 M 9 Y 1717-1G > A/R334W PRSS2: c.571G > A (G191R) ATP2C2: c.2381G > A (R794Q)
26 100 I 1 M 10 Y 1717-1G > A/R334W / /
27 79 S 25 Y na N1303 K/R334W / /
28 103 S 21 Y 21 Y N1303 K/R334W / LAMP2: c.586A > T (T196S)
29 64 S 4 Y 25 Y R553X /2789 + 5G > A KRT8: c.184G > T (G62C) /
30 93 S 2 M 6 Y 2789 + 5G > A/2789 +
5G > A
/ /
31 110 S 4 Y 4 Y [delta]F508/2789 + 5G >
A
CTRC: c.649G > A (G217S) /
32 76 S 16 Y na D614G/
((TG)11 T5;V562I;A1006E)
/ /
33 75 S 50 Y na [delta]F508/un CTRC: c.514A > G (K172E) /
34 69 I 3 M 14 Y N1303 K/H139R / /
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the trans-heterozygosity for mutations in the CFTR and
in other genes represents a risk factor for pancreatitis
even in patients with CF, as we recently demonstrated
for patients with idiopathic RP/CP (Sofia et al., 2016).
Among the genes encoding proteins involved in the
premature activation of trypsin, we found mutations in
14 patients with CF and RP/CP in PRSS1, PRSS2, CTRC,
CASR and KRT8 genes. Eight of such mutations were
known as pathogenic, while for other 6 mutations, three
bioinformatic tools predicted a pathogenic effect and the
ExAC tool reported the absence or the very low
frequency in the general population. Going in detail, we
found two mutations in PRSS1: the first is the
[c.592-11C > T;c.592-8C > T] complex allele was found
in two siblings. Keiles et al. (Keiles & Kammesheidt,
2006) described the same complex allele in an 18-years
old woman with pancreatitis; she also carried the
T908 N CFTR mutation. Furthermore, the PRSS1
splicing mutation c.592-24C > T previously described in
two siblings with CP (Singhi et al., 2014) was found in a
patient with the CFTR genotype [delta]F508/2789 +
5G > A. The patient carried also a KRT8 mutation.
Thus, we found three mutations in PRSS2. The T230I
and K98X mutations are novel. The T230I was reported
as pathogenic by the three bioinformatic tools; the K98X
is a nonsense mutation causing an early stop codon. The
third mutation in PRSS2 gene, i.e., the G191R, had been
analysed by Witt et al. (Witt et al., 2006). They demon-
strated that the recombinant G191R protein showed a
complete loss of trypsin activity owing to the introduc-
tion of a new tryptic cleavage site rendering the enzyme
hypersensitive to autocatalytic proteolysis. Furthermore,
we found three missense mutations in CTRC. The
K172E was identified in two patients. Masson et al. de-
scribed the K172E mutation in a patient with idiopathic
chronic pancreatitis (Masson et al., 2008). Thus, in two
other patients with the CFTR [delta]F508/G91G and
[delta]F508/2789 + 5G > A genotype we identified the
CTRC V235I and G217S missense mutations, respect-
ively. Rosendahl et al. investigated the functional conse-
quences of these two CTRC missense mutations through
transient transfections in HEK 293 T cells (Rosendahl et
al., 2008). They demonstrated that the G217S causes a
loss-of-function of the CTRC protein, whereas the V235I
results in normal or slightly reduced function, respect-
ively. Moreover, data observed in another report suggest
a role for the V235I mutation in triggering the pancre-
atic phenotype in a patient with CF (Tomaiuolo et al.,
2015). Rosendahl identified the G217S mutation also in
a healthy control and similarly, in our study we found it
in a patient with CF without RP/CP thus, we cannot
conclude on the pathogenic role of such mutation.
In addition, we found two missense mutations in
CASR: the V149I and the N189D; both the mutations
Table 2 Sweat chloride (mmol/L, SC), pancreatic status, age at CF and pancreatitis diagnosis, CFTR genotype and mutations in genes
related to intra-pancreatic activation of trypsin (IPAT) and pancreatic secretion pathway (PSP) genes in 48 patients with CF and
recurrent/chronic pancreatitis (Continued)
ID SC Pancreatic status Diagnosis
of CF (Age)
RP/CP onset CFTR genotype IPAT genes PSP genes
35 119 S 4 M 23 Y N1303 K/G85E / /
36 64 S 17 Y 49 Y S549R(A > C)/R334L / /
37 68 S 36 Y 24 Y [delta]F508/R334L / /
38 73 S 3 M 14 Y L997F/L320 V / TRPV1: c.1781C > T (A594V)
39 65 I 5 M 5 M [delta]F508/D110H KRT8: c.1073C > T (A358V) /
40 110 S 17 Y 32 Y [delta]F508/S945 L / /
41 81 S 35 Y 40 Y [delta]F508/2789 + 5G >
A
KRT8: c.184G > T (G62C);
PRSS1: c.592-24C > T
/
42 82 S 14 Y 28 Y R347P/R347P / /
43 91 S 25 Y 30 Y [delta]F508/2789 + 5G >
A
/ /
44 114 S 7 Y 23 Y [delta]F508/2789 + 5G >
A
/ /
45 116 S 1 M 19 Y [delta]F508/3272-26A >
G
/ /
46 84 S na 43 Y R1066H/T501I / /
47 76 I 3 M na [delta]F508/S549 N CASR: c.445G > A (V149I) TRPV5: c.1726G > A (A576T)
48 60 S 16 Y 30 Y [delta]F508/E193K CASR: c.565A > G (N189D) /
All mutations in IPAT and PSP genes were heterozygous with the exception of the c.1261C > T mutation in the TRPV1 gene (*) that was homozygous
S sufficiency, I insufficiency, M months, Y years, na not available, un unknown
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were considered pathogenic by bioinformatic tools and
by the very low frequency in the general population.
Finally, we found two missense mutations in KRT8.
The G62C was identified in two PS patients: the first
case had the R553X/2789 + 5G > A CFTR genotype and
the second had the [delta]F508/2789 + 5G > A CFTR
genotype in addition to the c.592-24C > T mutation in
PRSS1. Initially, the KRT8 G62C mutation was considered
pathogenic by Cavestro and coworkers (Cavestro et al.,
2003). Later, Witt et al. observed that the frequency of the
mutation did not differ between patients with acute or
chronic pancreatitis, pancreatic adenocarcinoma and
control individuals (Witt et al., 2006). Also in our study,
this mutation was found in a healthy subject. Thus, we
Table 3 Sweat chloride (mmol/L, SC), genotype of CFTR, intra-pancreatic activation of trypsin (IPAT) and pancreatic secretion
pathway (PSP) genes in patients with CF without chronic pancreatitis
N SC Pancreatic status Diagnosis of CF (Age) CFTR genotype IPAT genes (mutations) PSP genes (mutations)
1 93 S 25 Y [delta]F508/ [delta]F508 / /
2 98 I 14 Y F311 L/ M348 K/ W1145X / TRPV1: c.381C > A (C127X)
3 97 S 6 Y [delta]F508/ [delta]F508 / /
4 87 I 6 M [delta]F508 / c.2046_2047insA PRSS1/PRSS2 hybrid ATP2C2: c.643G > T (D215Y)
5 76 S 3 M G542X/ N1303 K / /
6 73 S 33 Y [delta]F508 / V562I/ A1006E / /
7 62 S 3 M S977F/ N1303 K / /
8 92 S 9 Y G85E/ R334L / /
9 76 I 9 M [delta]F508/I1234V / /
10 85 I 0 M N1303 K/L1077P / /
11 70 S 1 M G542X/2184insA / /
12 53 S 3 Y [delta]F508/P5L / /
13 79 I 10 Y R347P/P5L / /
14 135 I 4 M [delta]F508/2789 + 5G > A / /
15 99 I 10 M [delta]F508/S549R / /
16 60 I 2 M [delta]F508/991delC / /
17 87 I 11 Y R709X/ L1077P / /
18 79 S 4 Y [delta]F508/ I1234V /
19 142 S 0 M Q39X/ CFTRdele4–11 / /
20 98 S 4 M [delta]F508/CFTRdele2 /
21 98 I 5 Y [delta]F508/ Q685PfsX4 CTRC: c.649G > A (G217S) /
22 81 I 3 Y [delta]F508/T338I / /
23 80 I 2 M [delta]F508/P5L / /
24 65 I 2 M G178R/ CFTRdup19 / /
25 90 I 1 M [delta]F508 L732X / /
26 78 I 2 M [delta]F508/G542X / /
27 100 I 1 M [delta]F508/2789 + 5G > A / /
28 61 I 1 M [delta]F508/N1303 K / /
29 86 I 3 M 2789 + G > A/2789 + G > A / /
30 96 I 0 M [delta]F508/N1303 K / /
31 100 S 1 Y [delta]F508/E193K / /
32 70 I 6 M [delta]F508/N1303 K / /
33 111 I 46 Y [delta]F508/N1303 K / /
34 68 I 0 M [delta]F508/4040delA / /
35 100 S 33 Y [delta]F508/ [delta]F508 / TRPV1: c.1790C > T (T597 M)
Het heterozygous, na not available
S sufficiency, I insufficienc, na not available. All mutations in IPAT and in PSP genes were heterozygous
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cannot conclude on the pathogenic role of such mutation.
Finally, the KRT8 A358V novel mutation was identified in
a patient with the [delta]F508/D110H CFTR genotype and
we speculate on its pathogenetic role on the basis of the
bioinformatic prediction and of its absence in alleles from
the general population. Interestingly, in a recent study it
was demonstrated an interaction between KRT8 and the
CFTR protein that could influence the function of CFTR
(Treiber et al., 2006).
All the genes discussed so far are involved in the
premature intra-pancreatic activation of trypsin. This path-
way plays a pivotal role in triggering the activation cascade
Fig. 1 Flowchart of the results of molecular analysis in 48 patients affected by CF and recurrent/chronic pancreatitis (a), in 35 patients with CF
and without pancreatitis (b) and in 80 healthy subjects (c)
Table 4 Genotype of CFTR and mutations inintra-pancreatic activation of trypsin (IPAT) and pancreatic secretion pathway (PSP)
genes in in healthy controls
Patient ID IPAT genes PSP genes
ID-823 / ITPR3: c.2755G > T (G919C)
ID-1156 / SLC4A4: c.2528C > T (A843V)
ID-55 / TRPV5: c.256G > C (A86P)
ID-96 / ATP2C2: c.629C > T (T210 M)
ID-181 KRT8: c.184G > T (G62C) /
ID-182 / TRPV5: c.1490 T > C (M497 T)
ID-183 / SLC4A4: c.1805A > G (K602R); TRPV5: c.1490 T > C (M497 T)
ID-252 CASR: c.1672G > T (A558S) /
ID-508 / ITPR3: c.1574C > G (P525R)
ID-663 / ITPR3: c.1244 T > C (L415P)
ID-352 SPINK1: c.101A > G (N34S) /
All mutations in IPAT and in PSP genes were heterozygous
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of all pancreatic digestive zymogens caused by the breaking
of the interactions of these proteins in pancreas leading to
injury of acinar cells and consequently recurrent attacks of
pancreatitis (Sofia et al., 2016; Chen & Férec, 2009).
Moving to patients with CF without pancreatitis, we
found two cases with mutations IPAT genes: a patient
had the PRSS1/PRSS2 hybrid and a the CTRC G217S, a
mutation previously identified in a normal subject by
Rosendahl et al. (Rosendahl et al., 2008). In healthy sub-
jects, we identified three individuals with mutations in
SPINK1, CASR and KRT8 genes. The N34S mutation
identified in SPINK1 was described by Threadgold et al.
as a variation associated with a familial pattern of
idiopathic chronic pancreatitis (Threadgold et al., 2002).
Actually, it is considered not disease causing being
found in normal control too with an average prevalence
of 2.5% and an allele frequency of 1.25% (Premchandar
& s, 2017). The missense A558S identified in CASR is a
novel mutation considered potentially pathogenic by
bioinformatic analysis despite a frequency of about 1%
in the general population, while the KRT8 G62C muta-
tion found in another healthy control was identified also
in healthy subjects by Witt et al. (Witt et al., 2006).
All mutations found in the second group of 23 genes
PSP in the three groups of subjects were classified as
possibly damaging by the three bioinformatic tools and
all but two had a frequency in the general population <
0.1%. However, even if there is a trend of higher
frequency of such mutations in patients with CF and
RP/CP as compared to the patients with CF without
pancreatitis and to healthy controls, the difference is not
significant. To be noted that 6 out of 14 patients affected
by CF with RP/CP with mutations in genes encoding pro-
teins potentially involved in premature intra-pancreatic
activation of trypsin also have mutations in genes of the
pancreatic secretion pathway, in particular those belong-
ing to the Ca2+ signalling, pancreatic secretion and
autophagy pathways, further reinforcing the concept that
trans-heterozygous mutations in different genes may have
a synergic effect in the pathogenesis of RP/CP.
Conclusions
Our data strongly suggest that the trans-heterozygosity
for mutations in CFTR and in genes encoding proteins
involved in IPAT and PSP may enhance the risk for RP/
CP in patients with CF, as we previously demonstrated
in subjects with idiopathic RP/CP (Sofia et al., 2016).
Further studies are called, to define if patients with
trans-heteroygous mutations have a more severe out-
come of pancreatitis (the small number of cases limited
such evaluation in the present study) and functional
studies are necessary to elucidate the pathogenetic
mechanism of pancreatitis in patients bearing mutated
genes/proteins.
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